About Catalent: More Products. Better Treatments. Reliably Supplied

| October 10, 2011

article image
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 75 years of experience, we have the deepest expertise, the broadest offerings and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.

Spotlight

Shasun

Shasun Pharmaceutical Division develops & manufactures formulations for solid dosage products. Shasun is a vertically integrated formulations partner for the pharmaceutical industry and is focused on Europe, North America, Japan and other regulated markets. Its services include formulation research & development activities, analytical method development and validation, scale-up & technology transfer, clinical supplies manufacturing to full scale commercial manufacturing of oral solid dosage forms.

OTHER ARTICLES

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | March 26, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 26, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | March 26, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | March 26, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Shasun

Shasun Pharmaceutical Division develops & manufactures formulations for solid dosage products. Shasun is a vertically integrated formulations partner for the pharmaceutical industry and is focused on Europe, North America, Japan and other regulated markets. Its services include formulation research & development activities, analytical method development and validation, scale-up & technology transfer, clinical supplies manufacturing to full scale commercial manufacturing of oral solid dosage forms.

Events